TransCode Therapeutics, Inc. (RNAZ)
RNAZNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.54
+0.0500 (+3.36%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $26.24m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.45 to $12.60
- Average volume
- 54.6k
- Previous close
- $1.49
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$4.56m | -$16.03m | -$17.75m | -$6.79m |
| Net income | -$4.86m | -$13.44m | -$17.79m | -$6.75m |
News
8 latest- TransCode Therapeutics, Inc. Initiates Strategic Process to Maximize Value of TTX-MC138 and Oncology PortfolioFintel · Oct 29, 2026
- TransCode Reports Phase 1a Data For TTX-MC138 In Advanced Solid Tumors RTTNews · Oct 26, 2026
- Natera, TransCode Target Residual Colorectal Cancer With Trial Collaboration RTTNews · Oct 13, 2026
- After-Hours Biotech Gainers: TNON, BIVI, EDSA, RNAZ, HCWB RTTNews · Aug 18, 2026
- Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch RTTNews · Jul 9, 2026
- Top Biotech Gainers: CANF Climbs, RGNT Gears Up For Europe Launch, RNAZ, ELTX On Watch RTTNews · Jul 1, 2026
- Top Biotech Gainers: ABVX Soars On UC Trial Data, PMN Eyes Alzheimer's Catalyst, TRAX In Focus RTTNews · Jun 30, 2026
- Top Biotech Gainers: PBLS Soars Over 50%, CLOV Rallies On Legal Win, RNAZ, TMCI On Watch RTTNews · Jun 10, 2026
The company
TransCode Therapeutics is an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis, and is currently being evaluated in a Phase 2a trial under the PRE-I-SPY program in collaboration with Quantum Leap Healthcare Collaborative. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- transcodetherapeutics.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.